[email protected]

01252 375362

01252 375362

  • About Us
    • About Pharmacy Consulting
    • Our Team
    • Testimonials
  • Consultancy
    • For Pharmaceutical Wholesalers
    • For Pharmacies
    • Care Quality Commission – CQC
    • Pharmaceutical Manufacturers
    • Medical Devices Consultancy and Training
  • Academy Training
  • Bespoke Training
  • Our CPD
    • Blog
    • Editorial Items
    • Social Media
  • Contact Us
MHRA Response to contaminated paediatric medicines

MHRA Response to contaminated paediatric medicines

by Amelia Holmes | Oct 27, 2022 | Blog, GDP/RP, Good Distribution Practice - GDP, MHRA, Training

On the 7th of October The Medicines and Healthcare products Regulatory Agency (MHRA) released a response to contaminated paediatric medicines identified by the WHO region of Africa.

The Canada – United Kingdom Trade Continuity Agreement (CUK TCA) Protocol

The Canada – United Kingdom Trade Continuity Agreement (CUK TCA) Protocol

by Amelia Holmes | Sep 26, 2022 | Blog

The Canada – United Kingdom Trade Continuity Agreement (CUK TCA) was entered into force on the 1st of April 2021.

Defective Medicinal Products and Recall Management Guidance

Defective Medicinal Products and Recall Management Guidance

by Amelia Holmes | Aug 5, 2022 | Blog, MHRA

The main concerns with regard to possible defects of medicinal products and the substances used in their manufacture or packaging.

Import Licensed Human Medicine(s) to the United Kingdom (UK) – Guidance

Import Licensed Human Medicine(s) to the United Kingdom (UK) – Guidance

by Amelia Holmes | Jul 13, 2022 | Blog, MHRA, WDA(H), WDA(H)

Import Licensed Human Medicine – Prior to importation of a licensed medicine applications for the relevant Licence(s) must be completed and submitted which may include one or more of the following:

Import Unlicensed Human Medicine(s) to the United Kingdom (UK) – guidance

Import Unlicensed Human Medicine(s) to the United Kingdom (UK) – guidance

by Amelia Holmes | Jul 13, 2022 | Blog, Good Distribution Practice - GDP, MHRA, WDA(H)

An Introduced Product is an unlicensed medicine which can be imported from a country other than an approved country for import to be exported to a country other than an approved country for import, or if imported from a non-EEA country into Northern Ireland for export back to a country outside the EEA.

« Older Entries
Next Entries »

Recent Posts

  • CPD Accreditation – Directory listing
  • Tobacco and Vapes Bill becomes law
  • Medicines Supply Shortages and the impact on pharmacies when Drug Tariff prices do not keep up with the cost of drugs

Upcoming Courses

  • Intro to the Responsible Person (import) Role (Online) on 13 July 2026
  • GDP/RP Cogent Gold Standard Online Training on 21 July 2026
  • GDP Audit Online Training on 29 July 2026 10:00 am
  • Licence Holder Training on 3 August 2026 10:00 am
  • RP Forum – tbc on 4 August 2026 10:00 am

MHRA Alerts & Recalls

Class 2 Medicines Recall: Bristol Laboratories Limited, Phenoxymethylpenicillin 250 mg/5ml Sugar free Oral Solution BP, EL(26)A/33
9 July 2026
UPDATE: Class 4 Medicines Defect Notification: Relonchem Limited, Gabapentin Relonchem 50mg/ml Oral Solution, EL(26)A/31
7 July 2026
Field Safety Notices: 29 June to 03 July 2026
7 July 2026
Field Safety Notices: 22 to 26 June 2026
30 June 2026

Get In Touch

Address:
Wellesley House
10 Eelmoor Road
Farnborough
Hampshire
GU14 7QN

Phone: 01252 375362
Email: [email protected]
  • Terms and Conditions
  • Privacy Policy

Designed by Four Lakes

  • Follow
  • Follow
  • Follow
  • Follow